1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Issue Size
[.] shares (agg. up to ₹2,180 Cr)
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,598.34 | 1,579.65 | 1,294.79 | 989.99 |
| Total Income | 205.81 | 755.98 | 723.33 | 572.97 |
| Profit After Tax | 29.92 | 96.79 | 100.06 | 23.49 |
| EBITDA | 60.61 | 206.11 | 177.04 | 74.25 |
| NET Worth | 854.43 | 821.15 | 720.68 | 621.17 |
| Reserves and Surplus | 835.26 | 803.77 | 703.91 | 610.50 |
| Total Borrowing | 519.12 | 540.92 | 247.21 | 217.88 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹65.51 (+1.93%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹535.60 (-0.34%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,113.00 (+4.28%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,520.20 (-0.78%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹163.00 (-0.61%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.01 (-0.40%) |
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹138.70 (-0.18%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹38.13 (-4.65%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹185.00 (+0.00%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹273.75 (+0.09%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹255.30 (+2.51%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹112.00 (+1.82%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹254.50 (+1.13%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | 112.50 |
| 2 | General corporate purposes |
About Symbiotec Pharmalab IPO
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients, nutritional ingredients, and specialty products. The company caters to domestic and international markets across regulated and emerging regions. It emphasizes research-driven manufacturing, quality compliance, and sustainable processes. Symbiotec Pharmalab Ltd. supports pharmaceutical, nutraceutical, and wellness industries by delivering high-quality, innovative ingredients aligned with global standards. With over 30 years of industry experience, they have evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food and Drug Safety, Korea and other global organisations. As of June 30, 2025, they had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (“MT”) and fermentation capacity of 300 kilolitres. Competitive Strengths:
Contact Details
Symbiotec Pharmalab Ltd. Address385/2,Pigdamber, Rau,Mhow,Indore, Madhya Pradesh, 453331+91 731 667 6405secretarial@symbiotec.comVisit Website